Global Perspectives on Sequencing in Gastroesophageal Cancers : Episode 3

Next-Generation Sequencing for Gastric and GEJ Cancer

Jul 17, 2018

Transcript:

Related Videos

Michael K. Gibson MD, PhD

Dana B Cardin, MD, MSCI

Dana B Cardin, MD, MSCI

Laura Goff, MD

Mariana X. Byndloss, DVM, PhD

Michael K. Gibson MD, PhD

Laura Goff, MD

Michael K. Gibson MD, PhD

Andreana N. Holowatyj, PhD, MSCI, assistant professor of medicine and cancer biology, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center. Pannaga G. Malalur, MBBS

Related Content

FDA Approval Sought for Pembrolizumab Plus Chemotherapy in Biliary Tract Cancer

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Preoperative FOLFOX Is Noninferior to Preoperative Chemoradiation in Locally Advanced Rectal Cancer

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer

NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC

FDA Approval Sought for Pembrolizumab Plus Chemotherapy in Biliary Tract Cancer

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Preoperative FOLFOX Is Noninferior to Preoperative Chemoradiation in Locally Advanced Rectal Cancer

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer

NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC

FDA Approval Sought for Pembrolizumab Plus Chemotherapy in Biliary Tract Cancer

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Preoperative FOLFOX Is Noninferior to Preoperative Chemoradiation in Locally Advanced Rectal Cancer

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer

NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC

Related Content

Scot Ebbinghaus

FDA Approval Sought for Pembrolizumab Plus Chemotherapy in Biliary Tract Cancer

Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Deb Schrag, MD, FASCO, MPH

Preoperative FOLFOX Is Noninferior to Preoperative Chemoradiation in Locally Advanced Rectal Cancer

Nicholas Acuna, MPH

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

Shubham Pant, MD, MBBS

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer

Eileen M. O'Reilly, MD

NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC

Latest Conference Coverage

Dr Hamilton on the Efficacy and Safety of Abemaciclib Plus ET in Elderly Patients With HR+/HER2- Breast Cancer

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

Nivolumab Plus Relatlimab Demonstrates Consistent Benefit for Patients with Advanced Melanoma

Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.